News
  Date Title View
Jan 8, 2018
Data show that 95% of patients achieved clinical benefit after a single administration of ZILRETTATo date, 90% of eligible patients received a second administration between Weeks 12 and 24 BURLINGTON, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced init...
Dec 18, 2017
BURLINGTON, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has enrolled the first patient in a clinical trial to evaluate the pharmacokinetics and safety of ZILRETTATM (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthr...
Dec 13, 2017
Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a yearNew preclinical program holds potential to be a next-generation therapeutic that could provide long-lasting pain relief...
Dec 11, 2017
BURLINGTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company's Vice President of Medical Affairs, and in his new role, he assumes responsibility for all medical matters at Fl...
Dec 7, 2017
BURLINGTON, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the enrollment of the first patient in a clinical trial to evaluate the pharmacokinetics (PK) and safety of concurrent injections of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients w...
Dec 6, 2017
BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at the BMO Capital Markets Prescriptions for Success ...
Dec 4, 2017
BURLINGTON, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,500 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an effective date of December 1,...
Nov 28, 2017
BURLINGTON, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in an analyst-led fireside chat at the Evercore ISI Biopharma Catalyst/D...
Nov 20, 2017
Recently approved, non-opioid therapy now available for the management of osteoarthritis knee painLaunch of ZILRETTA commences with full complement of field sales personnel deployed across the U.S. BURLINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today ann...
Nov 17, 2017
Annual survey recognizes and honors the best employers in Massachusetts BURLINGTON, Mass., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project...
1
... NextLast
= add release to Briefcase